Effects of galantamine on measures of attention: Results from 2 clinical trials in Alzheimer disease patients with comparisons to donepezil

Alzheimer Disease and Associated Disorders

Volumn 22, Issue 1, 2008, Pages 30-38

  Galvin, James E ^a   Cornblatt, Barbara ^b   Newhouse, Paul ^c   Ancoli Israel, Sonia ^d   Wesnes, Keith ^e   Williamson, David ^f   Zhu, Young ^f   Sorra, Karin ^g   Amatniek, Joan ^f  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Cognitive Drug Research ^*  (United Kingdom)

^f JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^g Arroscience Inc   (Canada)

Author keywords

Alzheimer disease; Dementia; Galantamine; Nicotinic receptors

Indexed keywords

DONEPEZIL; GALANTAMINE; PLACEBO;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ATTENTION; BEDTIME DOSAGE; COGNITION; DRUG DOSE ESCALATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TASK PERFORMANCE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ATTENTION; CHOLINESTERASE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; GALANTAMINE; HUMANS; INDANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PIPERIDINES; SINGLE-BLIND METHOD;

EID: 43249087838     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e3181630b81     Document Type: Article

References (42)

1. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366:2112-2117.
2. Perry RJ, Watson P, Hodges JR. The nature and staging of attention dysfunction in early (minimal and mild) Alzheimer's disease: relationship to episodic and semantic memory impairment. Neuropsychologia. 2000;38:252-271.
3. Pignatti R, Rabuffetti M, Imbornone E, et al. Specific impairments of selective attention in mild Alzheimer's disease. J Clin Exp Neuropsychol. 2005;27:436-448.
4. Gorus E, De Raedt R, Lambert M, et al. Attentional processes discriminate between patients with mild Alzheimer's disease and cognitively healthy elderly. Int Psychogeriatr. 2006;18:539-549.
5. Galvin JE, Powlishta KK, Wilkins K, et al. Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study. Arch Neurol. 2005;62:758-765.
6. Wesnes K, Revell A. The separate and combined effects of scopolamine and nicotine on human information processing. Psychopharmacology (Berl). 1984;84:5-11.
7. Jones GM, Sahakian BJ, Levy R, et al. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology (Berl). 1992;108:485-494.
8. Pimlott SL, Piggott M, Owens J, et al. Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380. Neuropsychopharmacology. 2004;29:108-116.
9. Auld DS, Kornecook TJ, Bastianetto S, et al. Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol. 2002;68:209-245.
10. Dani JA, Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol. 2007;47:699-729.
11. Ellis JR, Ellis KA, Bartholomeusz CF, et al. Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans. Int J Neuropsychopharmacol. 2006;9:175-189.
12. Picciotto MR, Zoli M. Nicotinic receptors in aging and dementia. J Neurobiol. 2002;53:641-655.
13. Albuquerque EX, Pereira EF, Alkondon M, et al. Nicotinic acetylcholine receptors on hippocampal neurons: distribution on the neuronal surface and modulation of receptor activity. J Recept Signal Transduct Res. 1997;17:243-266.
14. Maelicke A. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease. Dement Geriatr Cogn Disord. 2000;11(suppl 1):11-18.
15. Wesnes K. The Cognitive Drug Research computerized assessment system: application to clinical trials. In: De Deyn PP, Thiery E, D'Hooge R, eds. Memory: Basic Concepts, Disorders and Treatment. Leuven: Uitgeverii Acco; 2003:453-472.
16. Rowan E, McKeith IG, Saxby BK, et al. Effects of donepezil on central processing speed and attentional measures in Parkinson's disease with dementia and dementia with Lewy bodies. Dement Geriatr Cogn Disord. 2007;23:161-167.
17. Vellas B, Cunha L, Gertz HJ, et al. Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease. Curr Med Res Opin. 2005;21:1423-1429.
18. Wesnes KA, McKeith IG, Ferrara R, et al. Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord. 2002;13:183-192.
19. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004;351:2509-2518.
20. Fakouhi TD, Jhee SS, Sramek JJ, et al. Evaluation of cycloserine in the treatment of Alzheimer's disease. J Geriatr Psychiatry Neurol. 1995;8:226-230.
21. Simpson P, Surmon D, Wesnes K, et al. The cognitive drug research computerized assessment for demented patients: a validation study. Int J Geriatr Psychiatry. 1991;6:95-102.
22. Ancoli-Israel S, Amatniek J, Ascher S, et al. Effects of galantamine versus donepezil on sleep in patients with mild to moderate Alzheimer disease and their caregivers: a double-blind, head-to-head, randomized pilot study. Alzheimer Dis Assoc Disord. 2005;19:240-245.
23. Wilcock G, Howe I, Coles H, et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging. 2003;20:777-789.
24. Wesnes KA, Ward T, McGinty A, et al. The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology (Berl). 2000;152:353-361.
25. Gorus E, Lambert M, De Raedt R, et al. The influence of galantamine on reaction time, attention processes, and performance variability in elderly Alzheimer patients. J Clin Psychopharmacol. 2007;27:182-187.
26. Caramelli P, Chaves ML, Engelhardt E, et al. Effects of galantamine on attention and memory in Alzheimer's disease measured by computerized neuropsychological tests: results of the Brazilian Multi-Center Galantamine Study (GAL-BRA-01). Arq Neuropsiquiatr. 2004;62:379-384.
27. Wesnes K, Edgar C. The relationship of GDS and MMSE assessments to domains of cognitive function assessed by the CDR system in Alzheimer's disease. Neurodegenerative Dis. 2007;4(suppl 1):288.
28. Wesnes KA, McKeith I, Edgar C, et al. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology. 2005;65:1654-1656.
29. Wesnes K, Harrison J, Edgar C, et al. The sensitivity and reliability of the Cognitive Drug Research computerized cognitive assessment system to disease progression and treatment response to Alzheimer's disease. Int Psychogeriatr. 2005;17(suppl 2):154.
30. Brodaty H, Corey-Bloom J, Potocnik FC, et al. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord. 2005;20:120-132.
31. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology. 2000;54:2261-2268.
32. Rockwood K, Mintzer J, Truyen L, et al. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry. 2001;71:589-595.
33. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology. 2000;54:2269-2276.
34. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ. 2000;321:1445-1449.
35. Bronnick K, Ehrt U, Emre M, et al. Attentional deficits affect activities of daily living in dementia-associated with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2006;77:1136-1142.
36. Stephens S, Kenny RA, Rowan E, et al. Association between mild vascular cognitive impairment and impaired activities of daily living in older stroke survivors without dementia. J Am Geriatr Soc. 2005;53:103-107.
37. Newhouse PA, Potter A, Kelton M, et al. Nicotinic treatment of Alzheimer's disease. Biol Psychiatry. 2001;49:268-278.
38. Newhouse PA, Sunderland T, Tariot PN, et al. Intravenous nicotine in Alzheimer's disease: a pilot study. Psychopharmacology (Berl). 1988;95:171-175.
39. Mentis MJ, Sunderland T, Lai J, et al. Muscarinic versus nicotinic modulation of a visual task. A pet study using drug probes. Neuropsychopharmacology. 2001;25:555-564.
40. Edwards JA, Wesnes K, Warburton DM, et al. Evidence of more rapid stimulus evaluation following cigarette smoking. Addict Behav. 1985;10:113-126.
41. Houlihan ME, Pritchard WS, Robinson JH. Faster P300 latency after smoking in visual but not auditory oddball tasks. Psychopharmacology (Berl). 1996;123:231-238.
42. Bates T, Pellett O, Stough C, et al. Effects of smoking on simple and choice reaction time. Psychopharmacology (Berl). 1994;114:365-368.